Imatinib resistance in gastrointestinal stromal tumors
- 1 August 2005
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 7 (4) , 293-299
- https://doi.org/10.1007/s11912-005-0053-6
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with ImatinibAnnals of Surgical Oncology, 2006
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumorsGastroenterology, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Salvage surgery for patients with recurrent gastrointestinal sarcomaCancer, 2000
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modelingElectrophoresis, 1997